Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
IMRX Immuneering
6.630
+0.060+0.91%
Pre Mkt Price
6.6300.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
-92.04% 38.38K -85.69% 94.42K -75.45% 183.7K -10.02% 2.08M
Operating revenue
-92.04% 38.38K -85.69% 94.42K -75.45% 183.7K -10.02% 2.08M
Cost of revenue
-91.17% 19.34K -84.97% 47.93K -77.80% 90.85K -9.94% 1.15M
Gross profit
-92.76% 19.04K -86.39% 46.49K -72.61% 92.85K -10.12% 926.89K
Operating expense
49.97% 13.21M 40.33% 11.69M 98.00% 13.02M 92.19% 34.81M
Selling and administrative expenses
47.60% 3.84M 176.42% 3.7M 233.78% 3.95M 165.98% 8.27M
-General and administrative expense
47.60% 3.84M 176.42% 3.7M 233.78% 3.95M 165.98% 8.27M
Research and development costs
50.85% 9.36M 14.15% 7.98M 68.03% 9.06M 76.90% 26.54M
Depreciation amortization depletion
-- 7.32K -- 7.32K -- 8.1K -- --
-Depreciation and amortization
-- 7.32K -- 7.32K -- 8.1K -- --
Operating profit
-54.37% -13.19M -45.75% -11.65M -107.28% -12.93M -98.37% -33.89M
Net non-operating interest income expense
1,181.52% 222.99K 4,281.68% 142.8K 1,985.07% 132.51K 298.30% 169.9K
Non-operating interest income
1,181.52% 222.99K 4,281.68% 142.8K 1,985.07% 132.51K 298.30% 169.9K
Other net income (expense)
1,593.82% 120.84K -24.05K -103.22K -127.06K
Other non- operating income (expenses)
1,593.82% 120.84K -- -24.05K -- -103.22K -- -127.06K
Income before tax
-50.51% -12.84M -44.32% -11.53M -107.02% -12.9M -98.61% -33.84M
Income tax
-307.49K
Net income
-50.51% -12.84M -44.31% -11.53M -107.02% -12.9M -96.81% -33.54M
Net income continuous Operations
-50.51% -12.84M -44.32% -11.53M -107.02% -12.9M -96.81% -33.54M
Minority interest income
Net income attributable to the parent company
-50.51% -12.84M -44.31% -11.53M -107.02% -12.9M -96.81% -33.54M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-50.51% -12.84M -44.31% -11.53M -107.02% -12.9M -96.81% -33.54M
Basic earnings per share
-4.26% -0.49 -31.59% -0.44 -6.52% -0.49 -23.62% -2.46
Diluted earnings per share
-4.26% -0.49 -31.59% -0.44 -6.52% -0.49 -23.62% -2.46
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
CEO: Dr. Benjamin J. Zeskind, PhD
Market: NASDAQ
Listing Date: 07/30/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist